A trial of intranasal Atrovent versus placebo in the treatment of vasomotor rhinitis.

Twenty-six patients with perennial rhinorrhea were treated by Atrovent, the anticholinergic agent, or placebo in a randomized double-blind crossover trial. The severity and duration of rhinorrhea were significantly reduced by Atrovent. Local side effects were more frequent with the active drug. These were reduced in a later open trial by a reduction in dosage.

RCT Entities:   Population Interventions Outcomes